Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge^® (omidubicel-onlv)